Brachyury-directed Vaccine for the Prevention or Treatment of Cancers
Posted Feb 20 2013 7:00pm
Description of Invention: Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers.
Researchers at the NIH have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to normal human tissues. Stimulation of T cells with the Brachyury peptide promoted a robust immune response and the targeted lysis of invasive tumor cells. Brachyury overexpression has been demonstrated in a range of human tumors (breast, lung, colon and prostate, among others) suggesting that a therapeutic vaccine derived from this technology would be broadly applicable for the treatment of cancer.
Preventative cancer vaccine for patients with precancerous lesions of the breast, colon or prostate.
Therapeutic cancer vaccine for the treatment of disseminated and late-stage tumors.
Vaccine component of a multi-modal cancer therapy.
Treatment targets invasive and metastatic tumor cells which are the primary cause of cancer-related mortality.
Vaccine can eliminate cancer stem cells which are resistant to conventional therapies.
Compatible with the clinically-proven TRICOM cancer vaccine platform.
Available (Optimized) for use with non-pox, non-yeast vectors including: adenovirus, lentivirus, etc., and for use with protein- or peptide-based vaccines.
Collaborative Research Opportunity: The National Cancer Institute Laboratory of Tumor Immunology and Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Brachyury-directed cancer vaccine technology. For collaboration opportunities, please contact John D. Hewes, Ph.D. at firstname.lastname@example.org . Click here to view the NCI collaborative opportunity announcement.